Man Group PLC Aquestive Therapeutics, Inc. Transaction History

Man Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.5 $483,790 - $942,448	-209,433 Reduced 94.3%	12,653 $32,000
Q1 2024 May 15, 2024	BUY	$2.01 - $6.09 $446,392 - $1.35 Million	222,086 New	222,086 $946,000
Q3 2023 Nov 14, 2023	SELL	$1.5 - $2.24 $127,459 - $190,339	-84,973 Reduced 66.1%	43,574 $66,000
Q2 2023 Aug 14, 2023	BUY	$1.06 - $2.49 $136,259 - $320,082	128,547 New	128,547 $212,000
Q1 2022 May 16, 2022	BUY	$2.28 - $4.26 $162,753 - $304,091	71,383 Added 385.5%	89,900 $235,000
Q4 2021 Feb 14, 2022	BUY	$3.69 - $6.37 $68,327 - $117,953	18,517 New	18,517 $72,000

122

46.8M

517K

207K

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $245M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.